0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Intravenous Immunoglobulin Therapy for Dystrophic Calcinosis Cutis: Unreliable in Our Hands

Andrew H. Kalajian, MD; Jennifer H. Perryman, MD; Jeffrey P. Callen, MD
Arch Dermatol. 2009;145(3):334. doi:10.1001/archdermatol.2008.620.
Text Size: A A A
Published online

Extract

We read with interest the recent report, “Response of Dystrophic Calcification to Intravenous Immunoglobulin,” by Schanz et al1 detailing the response to intravenous immunoglobulin (IVIg) of 1 patient with CREST syndrome–associated dystrophic calcification (CREST syndrome includes calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia). Because the more traditional medical therapies, including warfarin, diltiazem hydrochloride, probenecid, colchicine, and bisphosphonates, are seldom reliable, newer safe and effective therapies are sought.2 Unfortunately, while the success reported by Schanz et al is encouraging, we have experienced less success with IVIg therapy for dermatomyositis-associated dystrophic calcification.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure

Clinical appearance of patient with cutaneous eruption of dermatomyositis and dystrophic calcinosis cutis.

Graphic Jump Location

Tables

References

Correspondence

March 1, 2009
Stefan Schanz, MD; Anja Ulmer, MD; Gerhard Fierlbeck, MD
Arch Dermatol. 2009;145(3):335. doi:10.1001/archdermatol.2009.17.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

149 Views
7 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
PubMed Articles
[Dermatomyositis and polymyositis: clinical aspects and treatment]. Ann Med Interne (Paris) 2001;152(7):455-64.
Jobs
brightcove.createExperiences();